Michael Edwards, DO
Family Medicine · Orange Park, FLNPI 1437355302
Payments from drug & device makers
Across 445 payments — averaging $367.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$110K
- Biohaven Pharmaceutical Holding Company Ltd.$46K
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$581
- GSK$522
- plus $4K from 47 others
Across 9 payments — averaging $6184.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$56K
What the payments were for
- Food & beverage$7,77199%
- Education$1121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$189
- VRAYLAR$125
- PAINTEQ$121
- Ozempic$118
- mild Device Kit$105
- VENOVO$100
How this compares
$163,369 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Unoready PenSecukinumab | 13 | $112,112 |
| EnbrelEtanercept | 13 | $109,846 |
| OzempicSemaglutide | 70 | $96,154 |
| EliquisApixaban | 228 | $90,955 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $73,697 |
| MounjaroTirzepatide | 47 | $65,062 |
| JanuviaSitagliptin Phosphate | 31 | $47,704 |
| JardianceEmpagliflozin | 36 | $45,942 |
| Abilify MaintenaAripiprazole | 15 | $41,523 |
| LinzessLinaclotide | 52 | $40,667 |
| RybelsusSemaglutide | 19 | $39,357 |
| FarxigaDapagliflozin Propanediol | 37 | $36,912 |
| EntrestoSacubitril/Valsartan | 68 | $35,637 |
| TrulicityDulaglutide | 18 | $28,679 |
| Repatha SureclickEvolocumab | 33 | $21,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,032 | $135,51189 claims |
| AmgenEnbrel | $501 | $109,84613 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $522 | $100,084123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $400 | $93,74165 claims |
| PfizerEliquis | $109,717 | $90,955228 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $581 | $56,65878 claims |
| MerckJanuvia | $43 | $47,70431 claims |
| Boehringer IngelheimJardiance | $19 | $45,94236 claims |
| AbbVieLinzess, Synthroid | $1,211 | $43,35774 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $50 | $41,52315 claims |
| NovartisEntresto | $52 | $35,63768 claims |
| Johnson & JohnsonXarelto | $313 | $14,05013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Orange Park
- Michael StephensOrange Park$4.2M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.